StockData
Skye Bioscience, Inc. logo

Skye Bioscience, Inc. (SKYE) stock

SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$1.03+0.03 (+3.00%)

Close on Nov 18, 2026Market cap $36.48MP/E –Yield –

Skye Bioscience free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Skye Bioscience's free cash flow for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$43.07M. The highest annual figure on record is -$63.61K in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$43.07M–
FY2024Dec 31, 2024-$26.84M–
FY2023Dec 31, 2023-$13.96M–
FY2022Dec 31, 2022-$12.77M–
FY2021Dec 31, 2021-$6.57M–
FY2020Dec 31, 2020-$6.06M–
FY2018Dec 31, 2018-$3.95M–
FY2017Dec 31, 2017-$3.35M–
FY2016Dec 31, 2016-$3.56M–
FY2015Dec 31, 2015-$3.73M–
FY2013Oct 31, 2013-$63.61K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.12M–
Q1 FY2026Mar 31, 2026-$8.56M–
Q4 FY2025Dec 31, 2025-$9.77M–
Q3 FY2025Sep 30, 2025-$13.36M–
Q2 FY2025Jun 30, 2025-$10.75M–
Q1 FY2025Mar 31, 2025-$9.19M–
Q4 FY2024Dec 31, 2024-$8.22M–
Q3 FY2024Sep 30, 2024-$6.78M–
Q2 FY2024Jun 30, 2024-$7.13M–
Q1 FY2024Mar 31, 2024-$4.71M–
Q4 FY2023Dec 31, 2023-$3.85M–
Q3 FY2023Sep 30, 2023-$4.06M–
Q2 FY2023Jun 30, 2023-$1.99M–
Q1 FY2023Mar 31, 2023-$4.06M–
Q4 FY2022Dec 31, 2022-$4.88M–
Q3 FY2022Sep 30, 2022-$2.07M–
Q2 FY2022Jun 30, 2022-$2.90M–
Q1 FY2022Mar 31, 2022-$2.92M–
Q4 FY2021Dec 31, 2021-$2.02M–
Q3 FY2021Sep 30, 2021-$1.51M–
Q2 FY2021Jun 30, 2021-$1.67M–
Q1 FY2021Mar 31, 2021-$1.36M–
Q4 FY2020Dec 31, 2020-$1.79M–
Q3 FY2020Sep 30, 2020-$1.97M–
Q2 FY2020Jun 30, 2020-$1.03M–
Q1 FY2020Mar 31, 2020-$1.27M–
Q4 FY2018Dec 31, 2018-$1.01M–
Q3 FY2018Sep 30, 2018-$816.28K–
Q2 FY2018Jun 30, 2018-$1.06M–
Q1 FY2018Mar 31, 2018-$1.05M–
Q4 FY2016Dec 31, 2016-$662.78K–
Q3 FY2016Sep 30, 2016-$511.73K–

More Skye Bioscience figures

See a number that looks wrong?